

	Sex	Location	TB	HTN	HIV/AIDS	EtOH abuse	DM	CVD	Smoked	Malnutrition	Anemia	COPD	Cancer	Asthma	Malaria	Chronic kidney disease	Epilepsy	Sickle cell disease
40-44	F	COMMUNITY			✓													
25-29	M	COMMUNITY	✓		✓													
65-69	M	COMMUNITY														✓		
45-49	F	COMMUNITY	✓		✓	✓												
70-74	M	FACILITY		✓														
40-44	F	COMMUNITY	✓		✓													
25-29	M	COMMUNITY															✓	
85-89	M	COMMUNITY										✓	✓	✓				

Abbreviations: CVD – Cardiovascular disease; COPD – Chronic obstructive pulmonary disease, including emphysema and bronchitis; DM - diabetes mellitus (Type I and II not distinguished); HTN – hypertension; TB – tuberculosis

Supplementary figure: Distribution of CT values for all CV19 positive results, stratified by reactions against the N1 and N2 nucleocapsid gene targets using the US CDC CV19 assay kit.

The figure presents the distribution of CT results as proportions of all positive test results, stratified by the N1 and N2 targets used by the assay. Per the instructions of the manufacturer (US CDC), we declared a test 'positive' when the following criteria were met: 1) positive controls performed as expected on each plate; 2) negative controls were negative; 3) RNaseP was detectable for any given individual sample at a CT value <40; and 4) the CT values for both N1 and N2 reactions were < 40. For the expanded range analysis (CT values 40-45), all of these criteria also applied, except that we included results if there was a detectable N1 and N2 signal for a given sample at any level of detection. Ultimately, all results had a CT <43, indicating that the higher range CT results were quite close to the canonical threshold of 40.

